Marty Makary

I want to read this report that came from the Congressional National Security Commission on Emerging Biotechnology.

We're here at a biotech conference, so I figured we could start here because everyone's talking about China and the race against China.

We're here at a biotech conference, so I figured we could start here because everyone's talking about China and the race against China.

The US, according to this commission, has a three-year window to act to keep up with Chinese innovation and the speed in biotech.

The US, according to this commission, has a three-year window to act to keep up with Chinese innovation and the speed in biotech.

In 2022, Chinese companies were just 5% of licensing deals.

In 2022, Chinese companies were just 5% of licensing deals.

2025, 42%.

2025, 42%.

And recently, one of the biggest licensing deals ever was 3S Bio, $1.25 billion upfront with a $6 billion total with Pfizer.

And recently, one of the biggest licensing deals ever was 3S Bio, $1.25 billion upfront with a $6 billion total with Pfizer.

China had, 10 years ago, only 50% of published scientific papers to the US.

China had, 10 years ago, only 50% of published scientific papers to the US.

Today, they're 50% more than the US.

Today, they're 50% more than the US.

So I just want to walk through your view on US biopharma innovation as it relates to China.

So I just want to walk through your view on US biopharma innovation as it relates to China.

Is there a race?

Is there a race?

And if so, what are the priorities for the administration in helping American biotech industry remain competitive?